Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet

被引:81
作者
Gault, V. A. [1 ]
Porter, W. D. [1 ]
Flatt, P. R. [1 ]
Hoelscher, C. [1 ]
机构
[1] Univ Ulster, Sch Biomed Sci, SAAD Ctr Pharm & Diabet, Coleraine BT52 1SA, Londonderry, North Ireland
关键词
diet-induced obesity; exendin-4; GLP-1; object recognition; synaptic plasticity; GLUCAGON-LIKE PEPTIDE-1; DIABETES-MELLITUS; RECEPTORS; GLUCOSE; NEURONS; GLP-1; BETA;
D O I
10.1038/ijo.2010.59
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
High-calorie diet has been shown to impair learning ability and hippocampal synaptic plasticity in rodents. This study examined effects of daily treatment with the glucagon-like peptide-1 mimetic, exendin-4, on cognitive function and hippocampal synaptic plasticity in a model of diet-induced obesity, which exhibits compromised cognitive performance. Mice fed a high-fat diet were treated with exendin-4 (25 nmol kg(-1) bodyweight; twice daily) or saline vehicle (0.9% (w/v) NaCl) over 21 days. In addition to improving metabolic control, exendin-4-treated mice exhibited a marked increase in recognition index highlighting improved learning and memory. High-fat diet resulted in the elimination of in vivo electrophysiological long-term potentiation, which was rescued following exendin-4 treatment. This study shows that exendin-4 therapy improves cognitive function and ameliorates impaired hippocampal synaptic plasticity in dietary-induced obesity. International Journal of Obesity (2010) 34, 1341-1344; doi: 10.1038/ijo.2010.59; published online 30 March 2010
引用
收藏
页码:1341 / 1344
页数:4
相关论文
共 13 条
[1]   Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease [J].
Abbas, Talib ;
Faivre, Emilie ;
Hoelscher, Christian .
BEHAVIOURAL BRAIN RESEARCH, 2009, 205 (01) :265-271
[2]   Glucagon-like peptide-1 receptor is involved in learning and neuroprotection [J].
During, MJ ;
Cao, L ;
Zuzga, DS ;
Francis, JS ;
Fitzsimons, HL ;
Jiao, XY ;
Bland, RJ ;
Klugmann, M ;
Banks, WA ;
Drucker, DJ ;
Haile, CN .
NATURE MEDICINE, 2003, 9 (09) :1173-1179
[3]  
FLATT PR, 1981, DIABETOLOGIA, V20, P573
[4]   GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid [J].
Gault, Victor A. ;
Hoelscher, Christian .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 587 (1-3) :112-117
[5]   Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system [J].
Hamilton, Alison ;
Holscher, Christian .
NEUROREPORT, 2009, 20 (13) :1161-1166
[6]   Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure [J].
Hansotia, Tanya ;
Maida, Adriano ;
Flock, Grace ;
Yamada, Yuichiro ;
Tsukiyama, Katsushi ;
Seino, Yutaka ;
Drucker, Daniel. J. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (01) :143-152
[7]   Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier [J].
Kastin, AJ ;
Akerstrom, V ;
Pan, WH .
JOURNAL OF MOLECULAR NEUROSCIENCE, 2002, 18 (1-2) :7-14
[8]   Incretin-based therapies for type 2 diabetes mellitus [J].
Lovshin, Julie A. ;
Drucker, Daniel J. .
NATURE REVIEWS ENDOCRINOLOGY, 2009, 5 (05) :262-269
[9]  
McGovern S. F., 2009, NEUR ANN M SOC NEUR
[10]   Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron [J].
Perry, T ;
Lahiri, DK ;
Sambamurti, K ;
Chen, DM ;
Mattson, MP ;
Egan, JM ;
Greig, NH .
JOURNAL OF NEUROSCIENCE RESEARCH, 2003, 72 (05) :603-612